55 completed, 14 recruiting, 11 unknown, 7 active not recruiting. 103 Phase 2, 17 Phase 1, 14 Phase 3.
Follow Solutions: new trials by email Literature Review of Solutions trials Research Report on Solutions
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparative Study on Unani Formulation Vs Active Control in Plaque Psoriasis Marham Asfedaj, Mundij wa Mushil Sawda (Unani Oral decoction), Coal tar 1% & Salicylic acid 3 % solution - Chronic Plaque Psoriasis, Plaque Psoriasis | Phase 2 | Not yet recruiting | National Institute of Unani Medicine, Bengaluru | 54 | 2027-04-01 | 2026-09-25 |
| Safety and Efficacy Study of SKX-16 in Participants With Mild to Moderate Distal Subungual Onychomycosis SKX-16 (Luliconazole 10% Solution), Vehicle solution - Onychomycosis of Toenails | Phase 2 | Not yet recruiting | SATO Pharmaceutical Co., Ltd. | 204 | 2026-11-24 | 2026-11-10 |
| Rapid Rehydration for Severe Hypernatremia Intravenous Dextrose 5% solution - Hypernatremia | Phase 2 | Recruiting | Columbia University | 80 | 2026-10-22 | 2026-10-27 |
| Epidiolex Trial for Presymptomatic Treatment of Sturge-Weber Syndrome Epidiolex 100 mg/mL Oral Solution - Sturge - Weber Syndrome (SWS) | Phase 2 | Recruiting | Johns Hopkins University | 10 | 2026-09-17 | 2026-10-02 |
| Neo-adjuvant Immunotherapy in Patients With Localized Melanoma Ipilimumab (YervoyTM, 50 mg/10 mL solution), Nivolumab (OpdivoTM, 40 mg/4mL solution) - Cutaneous Melanoma, Stage III, Mucosal Melanoma | Phase 2 | Recruiting | UNICANCER | 50 | 2026-01-12 | 2026-07-21 |
| Evaluating Photodynamic Therapy Used to Treat Cutaneous Squamous Cell Carcinoma in Situ (isSCC) on the Face, Upper Extremities & Trunk. Aminolevulinic Acid 20% Topical Solution with Blue Light (dose 20 J/cm2), Aminolevulinic Acid 20% Topical Solution with Blue Light (dose 10 J/cm2) - Cutaneous Squamous Cell Carcinoma in Situ, Facial Cutaneous Squamous Cell Carcinoma in Situ | Phase 2 | Recruiting | The Center for Clinical and Cosmetic Research | 30 | 2025-11-25 | 2026-11-12 |
| Intravenous Alpha-1 Antitrypsin for Hospitalized Patients With COPD Exacerbations (AECOPD Study) alpha1-proteinase inhibitor, produced from the plasma of human donors (Prolastin 1000 mg, powder and solvent for solution for infusion), Placebo - Acute Exacerbation Chronic Obstructive Pulmonary Disease | Phase 2 | Not yet recruiting | Fondazione IRCCS Policlinico San Matteo di Pavia | 36 | 2025-10-01 | 2025-08-24 |
| A Study on the Treatment of Androgenetic Alopecia in Young Men With Umbilical Cord Mesenchymal Stem Cell Exosomes Human umbilical cord mesenchymal stem cell exosomes, Minoxidil 5% Topical Solution - Androgenic Alopecia | Phase 1 / Phase 2 | Recruiting | Shenzhen People's Hospital | 59 | 2025-09-20 | 2025-12-02 |
| Efficacy and Safety of Sodium Hyaluronate Gel Combined With Sodium Bicarbonate Versus Sodium Bicarbonate Alone in Prevention of Failed Back Surgery Syndrome Sodium hyaluronate jell, Sodium Bicarbonate, Saline - Postdiscectomy Epidural Fibrosis, Pain | Phase 2 / Phase 3 | Active not recruiting | Misr University for Science and Technology | 60 | 2025-06-20 | 2025-07-29 |
| Safety and Efficacy of Crofelemer in Adult Patients With Short Bowel Syndrome and Intestinal Failure (SBS-IF) Without Colon-in-continuity (CIC) Crofelemer Powder for Oral Solution, Matched Placebo Powder for Oral Solution - Short Bowel Syndrome, Malabsorption Syndromes | Phase 2 | Recruiting | Napo Therapeutics, S.p.A. | 18 | 2025-05-29 | 2026-06-09 |
| A Safety and Efficacy Study of PDFE-2304 Topical Solution for the Treatment of Androgenic Alopecia. Minoxidil 5% Topical Solution, PDFE-2304 Topical Solution - Alopecia, Androgenetic, Baldness | Phase 2 | Active not recruiting | PDFE Pharma Innovations FZCO | 15 | 2025-05-14 | 2025-06-08 |
| Ascending Doses of Crofelemer Powder for Oral Solution in Pediatric Microvillus Inclusion Disease (MVID) Crofelemer Powder for Oral Solution, Placebo Powder for Oral Solution - Microvillus Inclusion Disease, Congenital Disorders | Phase 2 / Phase 3 | Active not recruiting | Napo Pharmaceuticals, Inc. | 6 | 2025-05-01 | 2026-06-09 |
| Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma pembrolizumab (KEYTRUDA®), BI-1607, Ipilimumab (YervoyTM, 50 mg/10 mL solution) - Melanoma Metastatic, Melanoma of Skin | Phase 1 / Phase 2 | Active not recruiting | BioInvent International AB | 35 | 2024-12-11 | 2026-10-02 |
| Evaluating Cannabidiol as a Novel Anticraving Medication for Alcohol Use Disorder Oral solution - Alcohol Use Disorder | Phase 2 | Active not recruiting | Centre for Addiction and Mental Health | 36 | 2024-08-16 | 2026-11-02 |
| IVIG for Infection Prevention After CAR-T-Cell Therapy Immune Globulin Infusion (Human), 10% Solution, Anti-CD19 CAR T Cells Preparation, Saline - Hematologic Malignancies | Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 150 | 2024-06-10 | 2026-06-29 |
| Pembrolizumab in Progressive Multifocal Leukoencephalopathy (PML) in Immunocompromised Patients Without HIV Infection Pembrolizumab, 25 mg/ml solution for intravenous (IV) injection - Progressive Multifocal Leukoencephalopathy | Phase 2 / Phase 3 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 33 | 2024-04-01 | 2024-02-26 |
| A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases TAK-881, HYQVIA - Primary Immunodeficiency Diseases (PID) | Phase 2 / Phase 3 | Completed | Takeda | 65 | 2023-10-24 | 2026-09-30 |
| Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19) XNW5004, KEYTRUDA® (pembrolizumab) 25 mg/mL Solution for Injection - Carcinoma, Squamous Cell Carcinoma of Head and Neck | Phase 1 / Phase 2 | Terminated | Evopoint Biosciences Inc. | 12 | 2023-09-20 | 2026-07-23 |
| Study of Organ Perfusion in Heart Transplantation in Children Custodiol-N, Custodiol - Heart Transplantation | Phase 2 | Recruiting | Dr. F. Köhler Chemie GmbH | 15 | 2023-08-15 | 2026-01-30 |
| Evaluating the Use of Photodynamic Therapy to Treat Facial Cutaneous Squamous Cell Carcinoma in Situ (isSCC) Aminolevulinic Acid 20% Topical Solution with Blue Light - Facial Cutaneous Squamous Cell Carcinoma in Situ | Phase 2 | Completed | The Center for Clinical and Cosmetic Research | 32 | 2023-08-08 | 2025-02-12 |
Showing 20 of 103. Sign in to see all of them.
Alopecia (6) · Pain (5) · COVID-19 (4) · Pain, Postoperative (4) · Melanoma (3) · Primary Immunodeficiency Diseases (3) · Alcoholism (2) · Alopecia Areata (2) · Autoimmune Diseases (2) · Carcinoma, Squamous Cell (2) · Diabetic Neuropathies (2) · Hemangioma (2) · Hepatitis B (2) · Keratosis, Actinic (2) · Lichen Planus, Oral (2)
Aclaris Therapeutics, Inc. (2) · Allergan (2) · Assiut University (2) · Barinthus Biotherapeutics (2) · Baxalta now part of Shire (2) · BioInvent International AB (2) · DUSA Pharmaceuticals, Inc. (2) · Dompé Farmaceutici S.p.A (2) · The Center for Clinical and Cosmetic Research (2) · The University of Texas Health Science Center at San Antonio (2) · AbbVie (prior sponsor, Abbott) (1) · Ahmed Hassan Nouh MD (1) · Ain Shams University (1) · Apeptico Forschung und Entwicklung GmbH (1) · Assistance Publique - Hôpitaux de Paris (1)
United States (46) · Germany (11) · United Kingdom (10) · Spain (9) · France (7) · Italy (7) · Canada (6) · Egypt (5) · Denmark (4) · India (3) · Australia (2) · Austria (2) · China (2) · Finland (2) · Hungary (2)
Mark S Nestor, MD, PhD (2) · Stuart Marcus, MD, PhD (2) · Aaron Vinik, MD, PhD (1) · Abie Mendelsohn (1) · Alessandro Villa, DDS, PhD, MPH (1) · Alex Mullen (1) · Andrea Ardizzoni (1) · Andres McAllister, PhD (1) · Andrew Blauvelt, MD, MBA (1) · Angela E Rankine- Mullings, MD (1) · Angela Hansen (1) · Beth Drolet, MD (1) · Betsy Hughes-Formella, PhD (1)
PMID 10465169, PMID 10933492, PMID 11148177, PMID 11874817, PMID 12045122, PMID 12740257, PMID 12826636, PMID 15050036, PMID 15683545, PMID 18565211, PMID 19197072, PMID 19553648, PMID 19620039, PMID 19845686, PMID 20115946, PMID 20843247, PMID 21060150, PMID 21199096, PMID 21367592, PMID 21486454, PMID 21680942, PMID 21712909, PMID 21791473, PMID 21899919, PMID 22123804, PMID 22447964, PMID 22634722, PMID 23526215, PMID 23975926, PMID 23989916, PMID 24672709, PMID 25299856, PMID 25601618, PMID 25765294, PMID 26026936, PMID 26282478, PMID 26291554, PMID 26304913, PMID 26448169, PMID 27215779, PMID 27564664, PMID 27582171, PMID 27916480, PMID 28404617, PMID 29719508, PMID 30237305, PMID 30626238, PMID 30965011, PMID 31179005, PMID 31228628
2019 (4), 2017 (2), 2023 (2), 2014 (1), 2025 (1), R01AT011341 (1), R01CA276040 (1), R01DK149765 (1), R44DK104512 (1)